LOUVAIN-LA-NEUVE, Belgium, September 14, 2017
LOUVAIN-LA-NEUVE, Belgium, September 14, 2017 /PRNewswire/ --
DIAsource ImmunoAssays SA, the Belgian-based company specializing in development, sales and distribution of clinical diagnostics products, acquired this month the full assets of Viro-Immun Diagnostics GmbH, the German company specialized since 30 years in the development and manufacture of laboratory diagnostics for medical diagnosis of infectious and autoimmune diseases.
With this transaction, DIAsource acquires the Viro-Immun brand name and all ELISA and IFA products, as well as full inventory and infrastructure.
The company and brand Viro-Immun has a strong reputation for its complete portfolio of high quality assays in infectious and autoimmune diseases, spearheaded by the ToRCH panel with parameters such as Toxoplasma, Rubella, Herpes.
This acquisition fits in with DIAsource's strategy to act as a consolidator in its core business of manual kits and open automation. With this acquisition DIAsource strengthens and extends its established portfolio of proven best-in-class endocrinology and Vitamin D products.
BioVendor acquired 100% of the shares of DIAsource ImmunoAssays SA
Effective September 5th , 2017, BioVendor - Laboratorní medicína a.s. (BioVendor) acquired 100% of the shares of DIAsource ImmunoAssays SA from the Australian stock listed company, Anteo Diagnostics (ASX: ADO). Anteo Diagnostics had acquired DIAsource in January 2016.
For BioVendor, the international company with headquarters in Brno, Czech Republic, this acquisition offers an extension with a broad panel of ELISA and RIA assays, antibodies and reagents for clinical diagnostics, but also direct sales presence in Belgium, France and Spain, and a worldwide network of over 100 sales and distribution partners in over 70 countries.
With DIAsource representing the largest acquisition to date, BioVendor continues its long-term plan of international expansion after previous acquisitions since 2014 of ImmunoLab (Germany), ViennaLab Diagnostics (Austria), and Oxford Biosystems (UK), following to previous acquisition of TestLine Clinical Diagnostics (Czech Republic).
DIAsource ImmunoAssays SA -http://www.diasource-diagnostics.com, based in Louvain-La-Neuve, Belgium, manufactures and sells manual kits and open automation for clinical diagnostics in more than 70 countries worldwide, both direct and via its worldwide network of distribution partners. Turnover 16.3 Mi €.
BioVendor group - https://www.biovendor.com/biovendor-group, an international diagnostics holding, headquarters in Brno, Czech Republic, employs over 380 employees across 14 companies operating in six countries. BioVendor is 60% controlled by Consillium, the investment company of Mr. Tomáš Němec, and 40% owned by Dr. Viktor Růžička, its founder and Chairman.